《大行》里昂升科倫博泰(06990.HK)目標價至500.6元 重申「跑贏大市」評級
里昂發表報告指,科倫博泰生物-B(06990.HK)上半年營收按年減少31.3%,淨虧損1.45億人民幣,均好過預期。目標價由328.4元上調至500.6元,並重申「跑贏大市」評級。
報告指,公司首批中期產品銷售額為3.1億元人民幣,主要由sac-TMT帶動,而2L NSCLC的標籤擴大應進一步支持下半年的銷售增長。該公司將在2025年ESMO報告sac-TMT治療2L NSCLC和2L HR+ HER2-乳腺癌的III期結果,而涵蓋前線NSCLC和TNBC的多個III期試驗應在明年取得成果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.